Hepatosplenic gd T cell lymphoma (HSgdTCL) is very rare, representing o5% of all peripheral T cell lymphomas. Affecting mainly young men, HSgdTCL is characterized by pronounced hepatosplenomegaly without lymphadenopathy. 1 Despite a broad array of potential therapeutic approaches, HSgdTCL is very aggressive, with a median survival duration of o2 years. 2, 3 We report successful treatment with an unrelated donor cord blood transplantation (UCBT) following autologous peripheral blood stem cell transplantation (APBSCT) in a young woman with HSgdTCL.
A 25-year-old woman was admitted to our hospital because of massive splenomegaly (extending 15 cm below the left costal margin) and hepatomegaly (extending 5 cm below the right costal margin). The peripheral blood cell count was WBC, 2900/ml; Hb, 8.0 g/dl; and plt, 92 000/ml in a bone marrow aspirate, 12.8% of cells represented an infiltrate consisting of medium-size lymphocytes with pale cytoplasm and irregularly shaped nuclei without prominent nucleoli; the immunophenotype was CD2
, and TCR-gd þ (95.2%). Cytogenetic analysis indicated a normal karyotype; TCR-g gene rearrangement was detected by PCR analysis.
Computed tomography (CT) demonstrated marked hepatosplenomegaly without lymphadenopathy. Based on immunophenotype and imaging findings, the patient was diagnosed with HSgdTCL. PR was achieved after two cycles of the CHOP regimen, followed by another two courses of high-dose CY (2 g/m 2 on days 1 and 2) and high-dose MTX (4 g/m 2 on day 1). Subsequently, mobilization of PBSC was undertaken using etoposide plus G-CSF with a yield of 8.04 Â 10 6 CD34 þ cells/kg. Highdose therapy was begun with ranimustin (300 mg/m 2 on day À7), etoposide (400 mg/m 2 on days À6 to À3), and ifosfamide (3000 mg/m 2 on days À6 to À3), followed by reinfusion of PBSC. On day 28 after APBSCT, bone marrow examination indicated hematologic recovery without residual lymphoma cells, but CT still showed hepatosplenomegaly. Lymphoma cells were confirmed to be present in a specimen of the liver needle biopsy. Since the patient had no HLA-matched sibling and no matching unrelated donor was available, a decision was made to use an unrelated-donor cord blood transplant (UCBT)
/kg with a mismatch at two loci, HLA-A and DR. This transplant was performed 74 days after the APBSCT, following myeloablative conditioning with TBI (1200 cGy in four fractions), thiotepa (200 mg/m 2 on days À5 and À4), and CY (2250 mg/m 2 on days À3 and À2). GVHD prophylaxis included CsA and short-term MTX administration. Engraftment was confirmed on day 28 without significant treatment-related toxicity except for grade I acute GVHD. At the time of this writing, the patient has survived for more than 58 months since initial diagnosis without recurrence of disease.
Reported experience in attempting to treat HSgdTCL with chemotherapy, including high-dose chemotherapy with autologous transplantation, has been unsuccessful, 3 as in our case. Although reports of experience with allogeneic transplantation are limited, 3 demonstration of a graft-versus-lymphoma effect for this neoplasm would offer a potentially curative alternative for patients with HSgdTCL.
1,2,4 Of key importance to success is performance of allogeneic transplantation before the disease progresses, while the patient is in good clinical condition. We, therefore, recommend early allogeneic transplantation for this otherwise fatal disease. Unlike unrelated BM or PBSC, CB can be obtained promptly after the decision to perform allogeneic transplantation. CB is a reasonable alternative for patients with HSgdTCL who lack an HLA-matched sibling or a matching unrelated donor. Unfortunately, two fully ablative regimens carried out within a few months of each other impose a risk of significant toxicity and/or transplantation-related mortality. A reduced-intensity allogeneic transplantation protocol following autologous transplantation may solve this problem. 5 Another approach would be to proceed directly to fully ablative allogeneic transplantation for consolidative therapy, using CB or another appropriate stem cell source.
Yoshimatsu et al. 6 reported successful treatment of blastic natural killer cell lymphoma with UCBT. Although a graft-versus-lymphoma effect with CB and other allogeneic sources is in dispute, 7 our patient's successful outcome suggests that such an effect may exist for this neoplasm. UCBT may provide a long-term survival benefit for patients with auto-SCT-resistant HSgdTCL but with neither an HLA-matched sibling or a readily available matching unrelated donor, as suggested by this first report of such successful treatment.
